What Medtronic SCS devices are
Medtronic SCS devices are implantable spinal cord stimulation systems used as an aid in managing chronic, intractable pain of the trunk and limbs, including certain back, leg, and neuropathic pain patterns. In practical use, the system includes an implanted neurostimulator, one or more epidural leads, programming software, and a patient controller.
As of September 2026, Medtronic’s public SCS portfolio is centered on rechargeable systems such as Inceptiv and Intellis Pro or Intellis, along with the recharge-free Vanta system. The useful comparison is not simply which model is newest. For clinicians, payers, distributors, and hospital teams, the bigger questions are how each device manages therapy adjustment, battery use, MRI access, programming flexibility, and day-to-day patient maintenance. This overview is for industry education only and should not replace a physician’s evaluation. For broader coverage of spine technologies, see our spinal devices section.
Device options in the current Medtronic SCS portfolio
Medtronic’s SCS lineup has moved beyond earlier Restore and PrimeAdvanced platforms toward smaller implantable pulse generators, MRI-conditional labeling, body-position sensing, and more flexible programming options. Public FDA records and Medtronic product materials point to three practical decision categories: a rechargeable closed-loop system, rechargeable open-loop or position-adaptive systems, and a recharge-free primary-cell system.
| Device or platform | Battery approach | Main differentiator | Important qualification |
|---|---|---|---|
| Inceptiv SCS and Inceptiv LT | Rechargeable | Closed-loop sensing that can adjust stimulation in real time based on neural response; FDA PMA supplement decision dated April 24, 2024, with Medtronic announcement on April 26, 2024 | Closed-loop Neuro Sense use depends on compatible leads and labeling; sensing signals may not be measurable in all cases |
| Intellis Pro and Intellis | Rechargeable | Rechargeable platform with AdaptiveStim body-position-based adjustment, SureScan MRI technology under conditions, and support for Medtronic programming workflows such as DTM SCS where indicated | Requires a patient to manage recharging and follow device-specific MRI and programming instructions |
| Vanta | Recharge-free primary-cell battery | Designed for patients who may prefer not to recharge; includes AdaptiveStim and MRI-conditional access under specified conditions | Battery longevity is parameter-dependent, and eventual replacement surgery may be needed when the battery is depleted |
This is not a ranking. A patient with high energy requirements may be better suited to one battery strategy, while another may value avoiding routine recharging. A patient likely to need repeated MRI scans needs a different risk-benefit discussion from a patient whose main concern is manual dexterity, travel routine, or the ability to maintain a rechargeable implant.
What changed with Inceptiv closed-loop SCS
Inceptiv is the most important recent addition to the Medtronic SCS family because it shifts the platform from position-aware stimulation toward a closed-loop approach. Medtronic describes Inceptiv as a rechargeable SCS system that senses biological signals along the spinal cord and adjusts therapy in real time. FDA PMA supplement records identify Inceptiv LT Model 977117, Intellis Pro Model 977118, and Inceptiv Model 977119, along with the Neuro Sense closed-loop stimulation feature for specified Medtronic Vectris SureScan MRI 1×8 Compact Leads.
The clinical rationale for closed-loop SCS is that stimulation can feel different as posture changes and the distance between the lead and spinal cord shifts. A fixed-output system may deliver the same programmed output when the patient bends, lies down, coughs, or changes position. A closed-loop system attempts to measure neural response and adjust stimulation to maintain a more consistent dose. Medtronic materials also describe the use of evoked compound action potentials, or ECAPs, as part of the sensing concept.
How this differs from AdaptiveStim
AdaptiveStim, used in Medtronic systems such as Intellis and Vanta, is not the same as closed-loop neural sensing. AdaptiveStim uses body-position information to adjust stimulation according to programmed settings. Inceptiv’s closed-loop feature is presented as a step beyond position-based adjustment because it is designed to respond to a measured neural signal. In practice, both approaches still depend on patient selection, lead placement, programming quality, follow-up, and whether the patient’s pain pattern is appropriate for SCS.
Why compatibility matters
The FDA record for the 2024 Inceptiv approval is specific about associated system components. That detail matters because SCS performance and MRI eligibility are system-level issues, not pulse-generator issues alone. Leads, extensions, implanted generator model, software, and the patient programmer can all affect which features are available. A generator upgrade without compatible leads may not deliver the same feature set described in product materials.
Rechargeable versus recharge-free systems
The battery decision is one of the clearest practical differences among Medtronic SCS devices. Rechargeable systems such as Inceptiv and Intellis Pro are designed for repeated recharging over the life of the implant. They may support more energy-demanding therapy patterns, but the patient must maintain a charging routine. Recharge-free systems such as Vanta remove routine charging from daily device management, but battery life is finite and depends on amplitude, pulse width, frequency, active programs, and daily use.
Medtronic’s 2021 Vanta announcement described the platform as a next-generation recharge-free SCS system with battery life that could be optimized up to 11 years. More recent product materials stress the more practical point: recharge-free longevity varies with therapy settings. That distinction matters in clinical planning. A headline longevity figure is not a guarantee for an individual implant, particularly if programming requires higher energy use.
- Rechargeable systems may fit patients who can reliably charge the implant, need programming flexibility, or may require therapy settings that draw more energy.
- Recharge-free systems may fit patients who have trouble with charging routines, have limited dexterity, travel frequently, or strongly prefer lower day-to-day device maintenance.
- Neither approach is automatically better. The better option depends on diagnosis, trial response, expected programming, tolerance for replacement surgery, and patient preference.
Indications, evidence, and limits
Medtronic’s brief safety summaries describe SCS as an aid in managing chronic, intractable pain of the trunk and limbs, including unilateral or bilateral pain. FDA and company announcements also show important indication expansions. On January 24, 2022, Medtronic announced FDA approval of Intellis and Vanta for chronic pain associated with diabetic peripheral neuropathy. This was notable because painful diabetic neuropathy is common, progressive, and often difficult to manage with medication alone.
The evidence base for SCS is not uniform across all pain diagnoses. For selected neuropathic pain conditions, clinical societies have increasingly recognized SCS as an important option when conservative therapy is inadequate. The North American Neuromodulation Society has described evidence-based recommendations that strongly support SCS for painful diabetic neuropathy and persistent spinal pain syndrome type I, also called non-surgical low back pain. At the same time, Cochrane reviews and other evidence syntheses have cautioned that some low back pain evidence is limited, heterogeneous, or uncertain, especially when placebo-controlled comparisons and long-term durability are considered.
Medtronic’s DTM SCS program is another evidence-related consideration. DTM, or Differential Target Multiplexed SCS, is a proprietary waveform strategy associated with Medtronic platforms. Published and manufacturer-summarized randomized studies have compared DTM SCS with conventional SCS or conventional medical management in selected chronic back pain populations. These data are relevant to device evaluation, but they should not be read as a universal outcome promise. Trial response, diagnosis, surgical history, psychological screening, and comorbidities all influence results.
MRI, safety, and device-management considerations
MRI access is a major reason many SCS comparisons focus on Medtronic SureScan technology. Medtronic materials describe full-body MRI access for certain systems under specified conditions, and Inceptiv materials emphasize 1.5T and 3T MRI labeling under defined circumstances. The key phrase is under specified conditions. An implanted SCS system is not automatically MRI-safe because one component has MRI-related labeling. The complete implanted system must be identified, eligibility must be confirmed, and MRI mode or other required steps must be followed according to the device manual. See also: Implants.
Safety labeling remains central to device management. Medtronic’s SCS safety information lists diathermy as a contraindication because energy can transfer through an implanted system and cause severe injury or death. The same safety materials warn that electromagnetic interference from sources such as defibrillation, electrocautery, MRI, radiofrequency ablation, and therapeutic ultrasound can interact with the system. Patients with implanted cardiac devices require special assessment because electrical pulses and device electronics may interfere with one another.
Potential adverse events include uncomfortable stimulation, jolting or shocking sensations, hematoma, epidural hemorrhage, paralysis, seroma, infection, erosion, device malfunction, lead migration, implant-site pain, loss of pain relief, and other surgical risks. Patients with diabetes may have more frequent or severe surgical complications, so preoperative assessment is especially important when SCS is considered for diabetic peripheral neuropathy.
How clinicians often frame the choice
A structured device discussion usually begins before the permanent implant. Most SCS pathways include a temporary trial so the patient and clinician can evaluate pain relief, coverage, tolerability, and functional improvement before committing to an implanted generator. A trial does not guarantee long-term success, but it helps determine whether stimulation is likely to be useful for that patient’s pain pattern.
For Medtronic SCS devices, the most useful questions are specific rather than brand-centered:
- Is the pain diagnosis within the labeled indication and supported by current evidence?
- Will the trial measure only pain intensity, or also function, sleep, medication use, and activity tolerance?
- Is closed-loop sensing clinically relevant for this patient, or would position-based AdaptiveStim be sufficient?
- Can the patient reliably recharge a device, or would a recharge-free system reduce the maintenance burden?
- What MRI scans are likely in the future, and does the complete implanted system support those scans under labeling?
- Which leads are planned, and how do lead choices affect closed-loop features, MRI eligibility, and future revision options?
- How will complications, infection risk, lead migration, loss of relief, and device replacement be monitored over time?
For industry readers, Medtronic’s SCS direction is increasingly built around personalization, sensing, battery choice, MRI access, and programming workflows rather than a single stimulation mode. For patients and clinicians, the practical takeaway is narrower: the right SCS device is the one that fits the diagnosis, anatomy, expected imaging needs, daily maintenance capacity, and realistic treatment goals.
Frequently asked questions
Which Medtronic SCS device is the newest?
Inceptiv is Medtronic’s newer closed-loop rechargeable SCS platform, with FDA approval announced in April 2024. Availability and model options may vary by market, institution, and implanting physician.
Is Inceptiv better than Intellis or Vanta?
Not automatically. Inceptiv adds closed-loop sensing, while Intellis Pro and Intellis remain rechargeable options and Vanta offers recharge-free use. The best fit depends on the patient’s diagnosis, trial response, charging preference, MRI needs, and the clinician’s programming plan.
Can Medtronic SCS patients have MRI scans?
Many Medtronic SCS systems include SureScan MRI-conditional labeling, but MRI access depends on the complete implanted system and the exact conditions in the device manual. Patients should not assume MRI eligibility without confirmation from their care team.
Does a successful SCS trial guarantee permanent pain relief?
No. A trial can help predict whether stimulation may help, but long-term results can change because of disease progression, lead migration, scar tissue, programming changes, tolerance, infection, or other medical factors.
Is Vanta only for people who cannot recharge a device?
No. Vanta may appeal to anyone who prefers a recharge-free system, but it is especially relevant when charging would be inconvenient or difficult. The tradeoff is that battery life depends on settings, and replacement may eventually be required.